Infection with hepatitis C can lead to chronic hepatitis and cirrhosis of the liver, however this progression is not inevitable. Health professionals need to consider who may be at risk of the disease as the infection can be asymptomatic. If hepatitis C is diagnosed and the patient is found to have significant liver damage, treatment with ribavirin and injectable peginterferon alfa is indicated. These drugs can produce a sustained response in up to 90% of patients depending on the viral genotype. During treatment it is important to reduce other stresses on the liver such as a high alcohol consumption.
Introduction
Hepatitis C is a worldwide problem and in Australia over 280 000 people are estimated to have been infected by the hepatitis C virus. Not everyone infected with the virus requires drug treatment, but those that do may be untreated, despite the fact that combination antiviral therapy can achieve a sustained response in up to 90% of those infected with particular genotypes of the virus. This significant disparity between the number of infected individuals and the number treated exists despite a significant effort being directed towards improving the management of hepatitis C in the community. 1, 2, 3, 4, 5, 6 While many people have asymptomatic infection, a significant minority (15-20% over the course of 30 years) will progress through chronic hepatitis to cirrhosis and complications of cirrhosis, namely liver failure and hepatocellular carcinoma.
Hepatitis C is currently the most common indication for liver transplantation in Australia and many other Western countries.
This situation is unlikely to change in the immediate future.
Diagnosing hepatitis C
The majority of patients who contract hepatitis C are asymptomatic and unaware that they have the virus and that they can transmit the virus to others. Certain groups of people are at increased risk of being exposed to the virus and practitioners should discuss hepatitis C testing with these groups (see box).
It is important to routinely ask all patients questions about the possibility of blood-to-blood contact and possible blood-borne virus exposure to allow an appropriate assessment of the need for testing for blood-borne viruses.
Before testing, the meaning, implications, natural history, treatment options and notification requirements of a positive result need to be discussed.
Laboratory tests (Fig. 1 
After the diagnosis

Consider discussing and testing for hepatitis C in these groups
People who have:
■ received a blood product in Australia before 1990
■ received blood products in other countries 
Duration of therapy 6 months
Expected sustained viral response* 70-90%
Genotypes 1 and 4
Duration of therapy 12 months
Expected sustained viral response* 40-50%
* there is no hepatitis C RNA in the serum six months after completing treatment Who should be referred for hepatitis C antiviral therapy? (Fig. 2) All patients with signs of liver disease of any severity and those who wish to consider treatment should be referred to a liver In older patients it is wise to explore their family history of coronary artery disease and to perform an ECG if there is any suggestion that they may have asymptomatic coronary artery disease.
Follow-up
The care of patients is often shared between the liver unit and general practitioners. To assist general practitioners with monitoring their patients, liver units in Australia will normally provide a protocol for testing. Patients should be tested for liver function, full blood count and thyroid function second monthly and if there is concern other investigations may be ordered.
Conclusion
Hepatitis C itself is often not going to cause severe liver disease.
It is the combination of the viral infection plus factors such as alcohol excess, obesity, diabetes and haemochromatosis that leads to more severe liver disease. Addressing the secondary factors will lead to significant changes in liver function thus allowing a decision on requirements for antiviral therapy to be made in a more rational way.
